28 June 2022Partnership Announcement

We are proud to announce a partnership between Carmeda AB and Stryker’s Neurovascular division to develop flow diverter featuring the CARMEDA® BioActive Surface to advance brain aneurysm treatment.

Follow the link to view the full news release. Stryker´s news release

An aneurysm occurs when part of a blood vessel becomes weak, causing the vessel to balloon or bulge and fill with blood. If left untreated, the aneurysm may continue to weaken until it bursts and bleeds. Brain aneurysms are the most life-threatening and cause almost 500,000 deaths worldwide each year1.

The Stryker and Carmeda partnership will combine Stryker’s proven flow diverter technology with Carmeda’s active heparin coating to advance the treatment of brain aneurysms. Carmeda’s active heparin coating, the CARMEDA® BioActive Surface, is also known as CBAS® Heparin Surface.

1. Brain Aneurysm Foundation. Statistics and Facts Website. https://bafound.org/about-brain-aneurysms/brain-aneurysm-basics/brain-aneurysm-statistics-and-facts/ Accessed July 25, 2020

More News

Carmeda celebrates 35 years of saving and improving people’s lives
17June 2020
Carmeda, innovator and manufacturer of the CARMEDA® BioActive Surface for the medical device industry, is celebrating...
Read more
Area transplant recipient celebrates success of Berlin Heart
03October 2019
Berlin Heart EXCOR® Ventricular Assist Device supports the pumping function of a failing heart. This life-saving...
Read more
A life-saving collaboration
16May 2018
Check out the article about the successful collaboration between Carmeda and Berlin Heart in the spring issue of...
Read more